Form 4: Evolent Health CEO Seth Blackley Executes Stock Options and Sells Shares
SEC Form 4
Evolent Health's CEO, Seth Blackley, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan, while also adjusting his reported holdings due to a transfer of shares related to a domestic relations order.
Summary
- On August 22, 2024, Seth Blackley, CEO of Evolent Health, Inc., executed stock options to acquire 187,904 shares of Class A Common Stock.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 29, 2024.
- Blackley exercised options with exercise prices of $6.87 and $10.27.
- He sold 187,904 shares of Class A Common Stock at a weighted average price of $30.00.
- Blackley also transferred 348,458 shares of Evolent Health, Inc. Class A Common Stock pursuant to a domestic relations order.
- Following these transactions, Blackley directly owns 411,924 shares of Class A Common Stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The filing reflects routine transactions under a pre-existing trading plan and a transfer of shares due to a domestic relations order. There's no indication of positive or negative sentiment towards the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It is common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. The sale of shares may be for personal financial planning reasons and doesn't necessarily reflect a negative outlook on the company.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares by the CEO, but the pre-arranged trading plan mitigates concerns about insider trading.
- The transfer of shares due to a domestic relations order does not directly impact the company's operations or financial performance.
Key Dates
| Date | Description |
|---|---|
| February 29, 2024 | Date the reporting person adopted a Rule 10b5-1 trading plan. |
| August 22, 2024 | Date of the reported transactions, including option exercises and stock sales. |
| August 26, 2024 | Date of the signature on the Form 4 filing. |
| February 1, 2025 | Expiration date of some of the Class A Common Stock Options exercised. |
| March 1, 2026 | Expiration date of some of the Class A Common Stock Options exercised. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.